Sugi Predict

Sugi Predict / Compounds / SCHEMBL4420463

SCHEMBL4420463

SCHEMBL4420463

O=Cc1c(Cl)cc(CO)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ TDP1 Q9NUW8 2/20 0.44
▸ ACHE P22303 1/20 0.37
▸ ERN1 O75460 3/20 0.37
▸ HPGD P15428 2/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ NPC1 O15118 2/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ RECQL P46063 1/20 0.33
▸ CASP6 P55212 1/20 0.33
▸ LMNA P02545 1/20 0.32
▸ AOX1 Q06278 1/20 0.32
▸ HAO1 Q9UJM8 1/20 0.31
▸ ACLY P53396 1/20 0.31
▸ TRIM24 O15164 1/20 0.31
▸ TRIM33 Q9UPN9 1/20 0.31
▸ EGFR P00533 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5605398 0.84 ALDH1A1 (0.46) ALDH1A1MEN1KMT2ATDP1ERN1
SCHEMBL2642163 0.78 ACHE (0.42) ACHEHPGDKDM4ENPC1RAB9A
SCHEMBL5605331 0.77 IDO1 (0.46) ALDH1A1MEN1KMT2ATDP1
SCHEMBL5604727 0.77 ALDH1A1 (0.44) ALDH1A1MEN1KMT2ATDP1
SCHEMBL3913401 0.75 ERN1 (0.41) ALDH1A1ACHEERN1KDM4ESMN1; SMN2
SCHEMBL5604513 0.75 CYP1A2 (0.42) ALDH1A1MEN1KMT2ATDP1HPGD
SCHEMBL27661928 0.74 ALDH1A1 (0.41) ALDH1A1MEN1KMT2ATDP1
SCHEMBL1252250 0.74 FFAR1 (0.45) LMNAACLYCA2THRB
SCHEMBL209239 0.73 HSD17B10 (0.50) ALDH1A1MEN1KMT2ATDP1ERN1
SCHEMBL10705397 0.73 KDM4E (0.39) ALDH1A1MEN1KMT2ATDP1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1499577-B1 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES HOFFMANN LA ROCHE (CH) 2007-05-30 — — EP claimed
EP-1499577-A1 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2005-01-26 — — EP claimed
US-6790852-B2 HETEROCYCLIC NITROGEN COMPOUNDS SUCH AS 2-(2,6-DICHLOROPHENYL) -4-(3-BROMOPHENYL)-5-(2-(3- HYDROXYPROPYLAMINO)PYRIMIDIN-4-YL) -N-H-IMIDAZOLE, USED AS TYROSINE KINASE INHIBITORS; ANTICARCINOGENIC OR ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. 2004-09-14 — — US claimed
US-20030199691-A1 2-(2,6-dichlorophenyl)-diarylimidazoles F. HOFFMANN-LA ROCHE AG (CH) 2003-10-23 — — US claimed
WO-2003087026-A1 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2003-10-23 — — WO claimed
US-12528761-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2026-01-20 — — US disclosed
US-20230242471-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-08-03 — — US disclosed
US-20230242471-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-08-03 — — US disclosed
US-20230242471-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-08-03 — — US disclosed
EP-4168384-A1 THYROMIMETICS Autobahn Therapeutics, Inc. (US) 2023-04-26 — — EP disclosed
CN-115916740-A Thyromimetic agents 速通医疗公司 2023-04-04 — — CN disclosed
WO-2021257851-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. (US) 2021-12-23 — — WO disclosed
US-20050113342-A1 Novel imidazole derivatives and their use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2005-05-26 — — US disclosed
WO-2005040154-A1 NOVEL IMIDAZOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2005-05-06 — — WO disclosed
US-20050085473-A1 Novel triarylimidazoles HOFFMANN-LA ROCHE INC. 2005-04-21 — — US disclosed
EP-1499577-A1 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2005-01-26 — — EP disclosed
US-20040214874-A1 2-(2,6-Dichlorophenyl)-Diarylimidazoles BRANDT MICHAEL 2004-10-28 — — US disclosed
US-6790852-B2 HETEROCYCLIC NITROGEN COMPOUNDS SUCH AS 2-(2,6-DICHLOROPHENYL) -4-(3-BROMOPHENYL)-5-(2-(3- HYDROXYPROPYLAMINO)PYRIMIDIN-4-YL) -N-H-IMIDAZOLE, USED AS TYROSINE KINASE INHIBITORS; ANTICARCINOGENIC OR ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. 2004-09-14 — — US disclosed
US-20030199691-A1 2-(2,6-dichlorophenyl)-diarylimidazoles F. HOFFMANN-LA ROCHE AG (CH) 2003-10-23 — — US disclosed
WO-2003087026-A1 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2003-10-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085473-A1 Novel triarylimidazoles AURKAIP1, GLS2, GOT2 ALDH1A1 409/4885MEN1 1927/4885KMT2A 2396/4885
US-20050113342-A1 Novel imidazole derivatives and their use as pharmaceutical agents TUBB6, ABCB1, SDHA ALDH1A1 265/4885MEN1 608/4885KMT2A 3524/4885
US-20030199691-A1 2-(2,6-dichlorophenyl)-diarylimidazoles CYP2D6, CYP2F1, CYP1A2 ALDH1A1 115/4885MEN1 1726/4885KMT2A 933/4885
US-20040214874-A1 2-(2,6-Dichlorophenyl)-Diarylimidazoles CYP2D6, CYP1A2, CYP2F1 ALDH1A1 89/4885MEN1 1918/4885KMT2A 858/4885
US-12528761-B2 Thyromimetics TSHR, THRB, TTR ALDH1A1 1038/4885MEN1 1741/4885KMT2A 3776/4885
US-20230242471-A1 THYROMIMETICS TPO, THOP1, THRB ALDH1A1 1458/4885MEN1 708/4885KMT2A 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.